PNL2

Compound naevus

15/151

staining most prominent in junctional and superficial dermal melanocytes, similar to the pattern with HMB45

Dysplastic naevus

15/151

Blue naevus

2/21

homogenous diffuse positivity

PNL2

Melan-A

HMB45

Tyrosinase

MitF

positive for all markers

negative for all markers

positive ONLY for PNL2

Primary epithelioid melanoma

13/131

Metastatic melanoma

33/38(+:7, ++:3,+++:6,++++:17)1, 190/214(Cytoplasmic and often granular but in some cases shows a Golgi-zone accentuation.  Positivity of <10% of tumour cells in 23 cases, 10%-30% of tumour cells in 23 cases and >30% of tumour cells in 144 cases.  Positivity was seen in 25/30 cases negative for KBA62, 7/10 cases negative for S100, 7/28 cases negative for HMB45, 12/27 cases negative for Melan-A,4/16 cases negative for tyrosinase and in 1/10 cases which were negative for all but S100.) 4

31/38(+:4, ++:7,+++:5,++++:15)1

29/38(+:7, ++:5,+++:3,++++:14)1

35/38(+:4, ++:9,+++:5,++++:17)1

32/38(+:5, ++:4,+++:5,++++:18)1

26/381

1/381

2/381

Desmoplastic melanoma

1/131, 2/34(staining if present is focal)4

1/131

1/131

0/131

1/131

Non-desmoplastic spindle cell melanoma

4/51

Mucosal melanoma

48/544

Clear cell sarcoma

16/164

Angiomyolipoma

10/101, 14/174

18/18(staining stronger and more extensive than for HMB45 and MitF)2

18/182

1/153

15/153

15/16(liver and uterus)4

7/74

Lung

squamous carcinoma

0/11, 0/544

large cell carcinoma

0/454

adenocarcinoma

0/11, 0/324

Breast

ductal carcinoma

0/51, 0/664

lobular carcinoma

0/51, 0/54

Sarcomatoid carcinoma, intestine / larynx

0/394

Squamous cell carcinoma larynx

0/314

Squamous cell carcinoma oesophagus

0/254

Stomach, adenocarcinoma

0/484

Colon, adenocarcinoma

0/11, 0/484

Liver, cholangiocarcinoma

0/204

Liver, hepatocellular carcinoma

0/394

Pancreas, adenocarcinoma

0/274

Renal clear cell carcinoma

0/51

Ovarian carcinoma

0/51, 0/34(mainly serous carcinomas)4

Endometrium, adenocarcinoma

0/204

Squamous cell carcinoma cervix

0/224

Transitional cell carcinoma, bladder

0/51, 0/254

Prostate, adenocarcinoma

0/504

Embryonal carcinoma testis

0/224

Seminoma testis

0/434

Thyroid carcinoma

0/53(0/4 follicular, 0/49 papillary)4

Fibrosarcoma

0/41

Leiomyosarcoma

0/31

GIST, stomach and intestine

0/1034

Liposarcoma

0/51

Cellular dermatofibroma

0/51

Neurofibroma

0/51, 0/424

Schwannoma

0/174

Atypical fibroxanthoma

0/21

Cellular neurothekeoma

0/21

Granular cell tumour

0/11

MPNST

1/13(rare positive cells in one case with a focal rhabdomyosarcomatous component)1, 0/214

Melanotic Schwannoma

1/11

AML

0/51

CML

3/31, 6/64

0/144

0/364

0/324

0/1644

0/154